


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: **MOORE, et al.**

Application Number: 09/084,491

Filed: May 27, 1998

Title: **Tissue Plasminogen
Activator-Like Protease**



Group Art Unit: 1652

Examiner: Slobodyansky, E.

Attny. Docket No. PF378

#10
J.Q.J
10/20/99

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

Assistant Commissioner for Patents
Washington, D.C. 20231

SIR:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of an claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the references AA-BR listed on the attached form PTO 1449. A copy of references AA-AD and AF-BR is enclosed. A copy of reference AE (JP 10265498) will be submitted as soon as it becomes available.

The copy of reference AD (WO99/06548) enclosed herewith includes the specification, claims, and drawings in their entireties. However, because WO99/06548 recites 545 SEQ ID NOS over 666 pages, the copy of reference AD enclosed herewith includes only sequence listing information for SEQ ID NO:174 (i.e., the copy of reference AD enclosed herewith includes pages 240-242, and does not include pages 1-239 and 243-666, of the sequence listing of WO99/06548). Applicants respectfully assert that the copy of reference AD enclosed herewith contains all information relevant to the instant application, but will supply a copy of reference AD which includes the entire sequence listing (i.e., pages 1-666) upon the request of the Examiner.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application.

Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Science, Inc., deposit account no. 08-3425. A copy of this sheet is enclosed.

Respectfully submitted,

Dated: 10/14/99


Joseph J. Kenny
Agent for Applicants

(Reg. No. 43,710)

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (301) 610-5800

JJK/ur